Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Mobile applications have been considered to provide active and continuous support for smoking cessation. However, it is yet to be known whether a smoking cessation smartphone application improves long-term abstinence rates in nicotine-dependent patients. Objective: We aim to evaluate the long-term abstinence effect of a novel smartphone application, CureApp Smoking Cessation (CASC), in patients with nicotine dependence. Methods: This study was a prospective, interventional, multicenter, single-arm study. We provided the CASC application to all the participants, who used it daily for 24 weeks. The CASC application includes features to maximize the therapeutic effect of pharmacological therapies and counseling at outpatient clinics for smoking cessation. The primary endpoint was a continuous abstinence rate (CAR) from weeks 9 to 24, while secondary endpoints were CARs from weeks 9 to 12 and 9 to 52. Results: Of the 56 adult smokers recruited, one did not download the application; therefore, 55 participants constituted the full analysis sample. The CAR from weeks 9 to 24 was 63.6% (35/55; 95% confidence interval [CI]: 51.3% – 76.0%), while the CARs from weeks 9 to 12 and 9 to 52 were 76.4% (42/55; 95% CI: 65.2% – 87.5%) and 58.2% (32/55; 95% CI: 45.6% – 70.8%), respectively. These CARs were better than the results of the national survey on outpatient clinics with regard to smoking cessation under the National Health Insurance Program and that of the varenicline phase Ⅲ trial in Japan and the United States. There was only one participant who dropped out during the 12 weeks of the treatment period. This treatment decreased the scores related to withdrawal and craving symptoms. Conclusions: The addition of CASC to usual smoking cessation therapies resulted in high CARs, high patient retention rates, and improvement of cessation-related symptoms. The smartphone application CASC is a feasible and useful tool to help long-term continuous abstinence that can be combined with a standard smoking cessation treatment program. Clinical Trial: University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN ID: UMIN000020123).